Arbutus Biopharma Corp
NASDAQ:ABUS

Watchlist Manager
Arbutus Biopharma Corp Logo
Arbutus Biopharma Corp
NASDAQ:ABUS
Watchlist
Price: 4.78 USD -0.21% Market Closed
Market Cap: 919.3m USD

Net Margin
Arbutus Biopharma Corp

-289.5%
Current
-545%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-289.5%
=
Net Income
-42.3m
/
Revenue
14.6m

Net Margin Across Competitors

No Stocks Found

Arbutus Biopharma Corp
Glance View

Market Cap
917.5m USD
Industry
Biotechnology

Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).

ABUS Intrinsic Value
0.46 USD
Overvaluation 90%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-289.5%
=
Net Income
-42.3m
/
Revenue
14.6m
What is the Net Margin of Arbutus Biopharma Corp?

Based on Arbutus Biopharma Corp's most recent financial statements, the company has Net Margin of -289.5%.

Back to Top